Helicobacter pylori infection
Conditions
Interventions
Primary eradication therapy:Three drugs,i.e.,esomeprazole 20mg, amoxicillin 750mg, and clarithromycin 200mg, will be simultaneously administered twice daily for 7days. Secondary eradication therapy:T
Sponsors
Heiwadai clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients in whom H.pylori infection has been confirmed by serum anti-H.pylori antibody test or rapid urease test, and cultural method. 2) Patients who fall under at least one of the following matters. Patients with a history of gastric ulcer or duodenal ulcer. Patients with gastric MALT lymphoma. Patients with idiopathic thrombocytopenic purpura. Patients after endoscopic treatment of early-stage gastric cancer. Patients with H.pylori-induced gastritis.
Exclusion criteria
Exclusion criteria: 1) Patients with symptoms of hypersensitivity to the study drugs. 2) Patients with a history of H.pylori eradication. 3) Patients with a history of resection of gastrointestinal tract or vagal neurotomy. 4) Patients having peptic ulcer of stages other than the scarred stage as a complication. 5) Patients with warning findings such as vomiting and sudden weight loss. 6) Patients for whom participation in this study is difficult becaese of such complication as serious hepatic disease, renal disease, or cardiac disease. 7) Patients who have received PPI, histamin H2 receptor antagonist, selective muscarine receptor antagonist, anticholinergic drug, antacid, prostaglandin preparation, drug for reinforcing gastric mucosa protection factor, and bismuth preparation within 2 weeks before the diagnosis of H.pylori infection. 8) Women hwo are pregnant, lactating or who may be pregnant. 9) Patients for whom administration of any of following drugs is necessary. Atazanavir sulfate, pimozide, ergotamine or preparation containing ergotamine, tadalafil, SU, and colchicine. 10) Patients who are deemed ineligible as the subjects of study by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The overall eradication rate | — |
Secondary
| Measure | Time frame |
|---|---|
| H,pylori eradication rate by each regimen. H,pylori eradication rate by each factor including CYP2C19 genotype, drug-resistant bacteria, and any other backgrounds. Safety will be investigated on the basis of evaluation of adverse events. | — |
Countries
Japan
Contacts
Public ContactMotoyasu Chibai
Heiwadai clinic Surgery
Outcome results
None listed